A particular type of anemia in humans, called β-thalassemia, results from a severe reduction or absence of the normal β-globin chain of hemoglobin. However, the γ-globin chain, normally only expressed during fetal development, can functionally substitute for β-globin. A variety of studies have explored the use of the nucleoside 5-azacytidine for the expression of γ-globin in adult patients with β-thalassemia. How might 5-azacytidine lead to expression of γ-globin in adult patients?
Verified step by step guidance
1
Understand that β-thalassemia is caused by a reduction or absence of the β-globin chain, which is normally part of adult hemoglobin, and that γ-globin is typically expressed only during fetal development.
Recognize that 5-azacytidine is a nucleoside analog known to inhibit DNA methylation, a key epigenetic modification that can silence gene expression.
Recall that DNA methylation often represses gene expression by adding methyl groups to cytosine bases in DNA, particularly in promoter regions of genes, thereby preventing transcription factors from binding.
Consider that in adult patients, the γ-globin gene is usually silenced by methylation, so treatment with 5-azacytidine can reduce methylation levels, leading to reactivation of the γ-globin gene.
Conclude that by demethylating the γ-globin gene promoter, 5-azacytidine allows transcription machinery to access the gene, resulting in the expression of γ-globin chains that can substitute for missing β-globin in adult hemoglobin.
Verified video answer for a similar problem:
This video solution was recommended by our tutors as helpful for the problem above
Video duration:
1m
Play a video:
Was this helpful?
Key Concepts
Here are the essential concepts you must grasp in order to answer the question correctly.
β-Thalassemia and Globin Gene Expression
β-Thalassemia is a genetic disorder characterized by reduced or absent β-globin chains in hemoglobin, leading to anemia. Normally, β-globin is expressed after birth, while γ-globin is primarily expressed during fetal development. Understanding the switch from γ- to β-globin expression is key to exploring therapeutic strategies.
Gene expression can be regulated epigenetically through DNA methylation, which typically silences genes. In adult cells, the γ-globin gene is often methylated and inactive. Demethylation can reactivate these genes, allowing fetal hemoglobin production to resume, which is beneficial in β-thalassemia.
5-Azacytidine is a nucleoside analog that inhibits DNA methyltransferases, leading to hypomethylation of DNA. This demethylation can reactivate silenced genes like γ-globin in adult patients, promoting fetal hemoglobin production and compensating for defective β-globin in β-thalassemia.